101 related articles for article (PubMed ID: 17316966)
1. Complete response to the combination therapy with androgen blockade and somatostatin analogue in a patient with advanced prostate cancer: magnetic resonance imaging with 1H-spectroscopy.
Sciarra A; Panebianco V; Ciccariello M; Salciccia S; Gentilucci A; Lisi D; Passariello R; Gentile V; Di Silverio F
Eur Urol; 2008 Mar; 53(3):652-5. PubMed ID: 17316966
[TBL] [Abstract][Full Text] [Related]
2. Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer.
Cerulli C; Sciarra A; Salvatori G; Di Silverio F
Urology; 2004 Dec; 64(6):1231.e1-3. PubMed ID: 15596212
[TBL] [Abstract][Full Text] [Related]
3. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
Koutsilieris M; Mitsiades C; Dimopoulos T; Ioannidis A; Ntounis A; Lambou T
J Clin Endocrinol Metab; 2001 Dec; 86(12):5729-36. PubMed ID: 11739429
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer.
Di Silverio F; Sciarra A
J Urol; 2003 Nov; 170(5):1812-6. PubMed ID: 14532782
[TBL] [Abstract][Full Text] [Related]
5. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
[TBL] [Abstract][Full Text] [Related]
6. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
Mottet N; Peneau M; Mazeron JJ; Molinie V; Richaud P
Eur Urol; 2012 Aug; 62(2):213-9. PubMed ID: 22502942
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer.
Maulard C; Richaud P; Droz JP; Jessueld D; Dufour-Esquerré F; Housset M
Cancer Chemother Pharmacol; 1995; 36(3):259-62. PubMed ID: 7540120
[TBL] [Abstract][Full Text] [Related]
8. Lethal somatostatin analog-induced acute necrotizing pancreatitis in a patient with hormone-refractory prostate cancer.
Battaglia M; Ditonno P; Palazzo S; Bettocchi C; Garofalo L; Selvaggi FP
Scand J Urol Nephrol; 2006; 40(5):423-5. PubMed ID: 17060090
[TBL] [Abstract][Full Text] [Related]
9. Changes in body composition during androgen deprivation therapy for prostate cancer.
Smith MR; Finkelstein JS; McGovern FJ; Zietman AL; Fallon MA; Schoenfeld DA; Kantoff PW
J Clin Endocrinol Metab; 2002 Feb; 87(2):599-603. PubMed ID: 11836291
[TBL] [Abstract][Full Text] [Related]
10. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
11. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
12. Determination of the time for maximal response to neoadjuvant hormone therapy for prostate cancer using magnetic resonance with spectroscopy (MRSI) and dynamic contrast enhancement (DCEMR).
Sciarra A; Panebianco V; Salciccia S; Lisi D; Alfarone A; Gentilucci A; Parente U; Cattarino S; Passariello R; Gentile V
Urol Oncol; 2012 Sep; 30(5):614-9. PubMed ID: 21396849
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity.
Oh WK; Kaplan ID; Febbo P; Prisby J; Manola J; Kaufman DS; Kantoff PW
Am J Clin Oncol; 2003 Jun; 26(3):312-6. PubMed ID: 12796607
[TBL] [Abstract][Full Text] [Related]
14. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
15. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
16. Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid.
Drange MR; Melmed S
J Clin Endocrinol Metab; 1998 Sep; 83(9):3104-9. PubMed ID: 9745411
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC).
Mitsogiannis IC; Skolarikos A; Deliveliotis C
Expert Opin Pharmacother; 2009 Feb; 10(3):493-501. PubMed ID: 19191684
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
[TBL] [Abstract][Full Text] [Related]
19. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
[TBL] [Abstract][Full Text] [Related]
20. [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
Mizusawa H; Kontani K; Okaneya T; Yoneyama T
Hinyokika Kiyo; 1997 Jun; 43(6):421-3. PubMed ID: 9250492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
